KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Deferred Tax (2017 - 2025)

Vertex Pharmaceuticals has reported Long-Term Deferred Tax over the past 9 years, most recently at $2.9 billion for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $2.9 billion for Q4 2025, up 24.31% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (up 24.31% YoY), and the annual figure for FY2025 was $2.9 billion, up 24.31%.
  • Long-Term Deferred Tax for Q4 2025 was $2.9 billion at Vertex Pharmaceuticals, down from $2.9 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for VRTX hit a ceiling of $2.9 billion in Q3 2025 and a floor of $815.9 million in Q1 2021.
  • Median Long-Term Deferred Tax over the past 5 years was $1.6 billion (2023), compared with a mean of $1.7 billion.
  • Biggest five-year swings in Long-Term Deferred Tax: fell 28.91% in 2021 and later skyrocketed 48.71% in 2023.
  • Vertex Pharmaceuticals' Long-Term Deferred Tax stood at $934.5 million in 2021, then surged by 33.43% to $1.2 billion in 2022, then soared by 45.33% to $1.8 billion in 2023, then rose by 28.64% to $2.3 billion in 2024, then rose by 24.31% to $2.9 billion in 2025.
  • The last three reported values for Long-Term Deferred Tax were $2.9 billion (Q4 2025), $2.9 billion (Q3 2025), and $2.7 billion (Q2 2025) per Business Quant data.